Soligenix (SNGX) Long-Term Investments (2019 - 2021)
Soligenix's (SNGX) quarterly Long-Term Investments came in at $106155.0 in Q4 2021, down 53.45% YoY from $228027.0 in Q4 2020, and down 22.13% on a QoQ basis from $136321.0 in Q3 2021.
Soligenix (SNGX) Long-Term Investments (2019 - 2021) Analysis & Trends
Soligenix (SNGX) has 3 years of Long-Term Investments data on file, last reported at $106155.0 in Q4 2021.
- Quarterly Long-Term Investments fell 53.45% year-over-year to $106155.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $106155.0 (down 53.45% YoY) and the FY2021 annual result came in at $106155.0, down 53.45% from the prior year.
- Long-Term Investments declined to $106155.0 in Q4 2021, from $136321.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $259837.0 in Q3 2020 to a low of $55393.0 in Q2 2020.
- A 3-year average of $161965.8 and a median of $163401.5 in 2019 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2020 — Long-Term Investments slumped 71.18% — and 2021, when it surged 202.58%.
- Tracing SNGX's Long-Term Investments over 3 years: stood at $125412.0 in 2019, then soared by 81.82% to $228027.0 in 2020, then slumped by 53.45% to $106155.0 in 2021.
- The last three Long-Term Investments figures came in at $106155.0 (Q4 2021), $136321.0 (Q3 2021), and $167608.0 (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 106,155.00 |
| Sep 30, 2021 | 136,321.00 |
| Jun 30, 2021 | 167,608.00 |
| Mar 31, 2021 | 198,171.00 |
| Dec 31, 2020 | 228,027.00 |
| Sep 30, 2020 | 259,837.00 |
| Jun 30, 2020 | 55,393.00 |
| Mar 31, 2020 | 90,821.00 |
| Dec 31, 2019 | 125,412.00 |
| Sep 30, 2019 | 159,195.00 |
| Jun 30, 2019 | 192,200.00 |
| Mar 31, 2019 | 224,449.00 |